Polarean Imaging PLC Appointment of Chief Financial Officer (2716X)
29 Abril 2019 - 1:02AM
UK Regulatory
TIDMPOLX
RNS Number : 2716X
Polarean Imaging PLC
29 April 2019
29 April 2019
Polarean Imaging Plc
("Polarean" or the "Company")
Appointment of Chief Financial Officer
Polarean Imaging plc (AIM: POLX) Polarean Imaging plc (AIM:
POLX), the clinical stage medical-imaging technology company, with
a proprietary drug-device combination product for the magnetic
resonance imaging (MRI) market, announces the appointment of
Charles (Chuck) Osborne, Jr as Chief Financial Officer (CFO) with
immediate effect. Chuck Osborne's role is a non-board
appointment.
Mr. Osborne joins the Company from Innocrin Pharmaceuticals Inc
("Innocrin"), a privately held oncology therapeutics company where
he was CFO since 2015. Prior to his role at Innocrin, Mr. Osborne
was CFO of Scynexis Inc, a publicly traded anti-infective company
between 2003 and 2015. Mr. Osborne holds a Bachelor of Science
degree in Business Administration, with a Concentration in
Accounting, from University of North Carolina. He is a Certified
Public Accountant and began his accounting career at Deloittie
& Touche in 1988.
Mr. Osborne will replace the Company's current CFO Bill Patrick,
who will stay with Polarean in the role of Financial Controller to
Polarean Inc, the Company's wholly owned subsidiary.
Richard Hullihen, CEO of Polarean Imaging, commented on the
appointment: "We are delighted to welcome Chuck to Polarean's
management team. Chuck's previous capital markets experience
coupled with his knowledge of financial operations within the
pharmaceutical industry will ensure strong leadership of the
Company's financial function.
"On behalf of the Board, I would like to thank Bill Patrick for
all his efforts and input to date both operationally and
financially through the Company's admission to AIM last year and in
the period since. Mr Patrick's involvement with the Company will
continue with his new role of Financial Controller for Polarean
Inc."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
David Hignell / Lindsay Mair / Jamie Spotswood
(Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44
(0)7879 741 001
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPGUCUCUPBGGQ
(END) Dow Jones Newswires
April 29, 2019 02:02 ET (06:02 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024